Fig. 3
The estrogen regulating property of IGBN. a Representative CLSM images of biodistribution of FITC-labeled IGBN for different time treatment to 4T1 cells. Cell nuclei: blue, NPs: green, lysosome: red, scale bar: 7.5 μm. b The intensity profile along the white line in the merged image. c Mean fluorescence intensity (MFI) of FITC in IGBN treated cells for different times (n = 3). d Flow cytometer analysis of FITC-labeled IGBN treated cells for different incubation times. e Cu content in 4T1 cells after treated with IGBN for 8 h (n = 3). f Intracellular GSH levels in 4T1 cells treated with CD (DSPE-PEG2000 modified Cu-GA MOF), PA (Cisplatin-arginine) and IGBN for 24 h, respectively (n = 3). g The potential mechanism of estrogen-driven TNBC metastasis. h Western blot assay and i semi-quantitative analysis of Capn-4 and MMP-2 in 4T1 cells with estradiol and calpeptin (Capn4 inhibitor) treatments (n = 3). j Western blot assay, k and l semi-quantitative analysis of p-ERK, ERK, Capn-4 and MMP-2 in 4T1 cells with estradiol and PD98059 (ERK inhibitor) treatments. m Capn-4 and n MMP-2 levels in 4T1 cells treated with different formulations (n = 3). CPD (CD loaded with cisplatin) o E2 and p 4-OHE2 level after 4T1 cells treated with different formulations (n = 3). Results are presented as means ± s.d. Statistical significance was calculated by Student’s t-test. **P < 0.01, ***P < 0.001